Analytical Data
-
Gene name
CD83
- Application
-
Alternative Names
BL11; HB15; Activated B Lymphocytes,Immunoglobulin; B-cell activation protein; Cell surface protein HB15
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q01151
-
Expression Region
Thr20~Glu144
-
Molecular Weight
18kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD83 is a critical molecule involved in the regulation of immune responses, primarily expressed on the surface of dendritic cells and other antigen-presenting cells. It plays a pivotal role in promoting T cell activation and co-stimulation, making it essential for effective immune system function. The study of CD83 has gained significant interest in recent years due to its potential implications in various therapeutic areas, including cancer immunotherapy, autoimmune diseases, and vaccine development. Recombinant CD83 protein has been developed for research purposes to elucidate its biological functions and interactions. By producing CD83 as a recombinant protein, researchers can investigate its mechanisms of action, assess its role in immune regulation, and explore its potential as a therapeutic target. Furthermore, recombinant CD83 can be utilized as a biomarker for disease progression or response to treatments. The continued exploration of CD83 and its recombinant forms may lead to novel strategies in modulating immune responses, paving the way for innovative treatments that enhance immune efficacy against malignancies and improve patient outcomes in immunological disorders. As the understanding of CD83's role in immune regulation deepens, it promises to become an integral component of future immunotherapeutic approaches.
